VioQuest Pharmaceuticals, Inc. (VOQP)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2007 | 1.35 Million USD | -76.69% |
| 2006 | 5.82 Million USD | -30.44% |
| 2005 | 8.37 Million USD | 71.82% |
| 2004 | 4.87 Million USD | 207.51% |
| 2003 | 1.58 Million USD | -51.7% |
| 2002 | 3.28 Million USD | 1468.1% |
| 2001 | 209.38 Thousand USD | -32.36% |
| 2000 | 309.54 Thousand USD | -10.64% |
| 1999 | 346.41 Thousand USD | 16.08% |
| 1998 | 298.42 Thousand USD | -1.56% |
| 1997 | 303.15 Thousand USD | -24.78% |
| 1996 | 403.02 Thousand USD | 4.61% |
| 1995 | 385.25 Thousand USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2008 Q1 | 698.23 Thousand USD | -48.6% |
| 2008 Q2 | 1.17 Million USD | 68.62% |
| 2007 Q2 | 5.69 Million USD | 48.74% |
| 2007 Q3 | 3.45 Million USD | -39.3% |
| 2007 Q4 | 1.35 Million USD | -60.7% |
| 2007 Q1 | 3.82 Million USD | -34.31% |
| 2007 FY | 1.35 Million USD | -76.69% |
| 2006 FY | 5.82 Million USD | -30.44% |
| 2006 Q1 | 6.03 Million USD | -27.94% |
| 2006 Q2 | 5.15 Million USD | -14.56% |
| 2006 Q3 | 3.73 Million USD | -27.51% |
| 2006 Q4 | 5.82 Million USD | 55.87% |
| 2005 Q4 | 8.37 Million USD | 220.65% |
| 2005 Q1 | 3.75 Million USD | -23.02% |
| 2005 Q2 | 3.28 Million USD | -12.47% |
| 2005 FY | 8.37 Million USD | 71.82% |
| 2005 Q3 | 2.61 Million USD | -20.48% |
| 2004 Q3 | 5.53 Million USD | -13.68% |
| 2004 Q1 | 7.48 Million USD | 371.78% |
| 2004 Q4 | 4.87 Million USD | -11.91% |
| 2004 FY | 4.87 Million USD | 207.51% |
| 2004 Q2 | 6.41 Million USD | -14.27% |
| 2003 Q2 | 2.43 Million USD | -15.01% |
| 2003 FY | 1.58 Million USD | -51.7% |
| 2003 Q4 | 1.58 Million USD | -11.76% |
| 2003 Q3 | 1.79 Million USD | -26.33% |
| 2003 Q1 | 2.87 Million USD | -12.57% |
| 2002 Q3 | 3.21 Million USD | 11.29% |
| 2002 FY | 3.28 Million USD | 1468.1% |
| 2002 Q4 | 3.28 Million USD | 2.21% |
| 2002 Q2 | 2.88 Million USD | 4171.67% |
| 2002 Q1 | 67.57 Thousand USD | -67.73% |
| 2001 Q2 | 235.87 Thousand USD | -15.66% |
| 2001 Q3 | 204.87 Thousand USD | -13.14% |
| 2001 Q4 | 209.38 Thousand USD | 2.2% |
| 2001 FY | 209.38 Thousand USD | -32.36% |
| 2001 Q1 | 279.68 Thousand USD | -9.65% |
| 2000 Q4 | 309.54 Thousand USD | -5.98% |
| 2000 Q3 | 329.24 Thousand USD | -15.77% |
| 2000 FY | 309.54 Thousand USD | -10.64% |
| 2000 Q1 | 344.75 Thousand USD | 0.0% |
| 2000 Q2 | 390.9 Thousand USD | 13.38% |
| 1999 FY | 346.41 Thousand USD | 16.08% |
| 1998 FY | 298.42 Thousand USD | -1.56% |
| 1997 FY | 303.15 Thousand USD | -24.78% |
| 1996 FY | 403.02 Thousand USD | 4.61% |
| 1995 FY | 385.25 Thousand USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 2310.00 USD | -58703.16% |
| Arch Therapeutics, Inc. | 1.95 Million USD | 30.632% |
| Evofem Biosciences, Inc. | 10.55 Million USD | 87.129% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -146.025% |
| Rebus Holdings, Inc. | 5000.00 USD | -27067.06% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | 98.957% |
| Qrons Inc. | 420.00 USD | -323317.381% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -76.262% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | 95.139% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -182.662% |
| Skye Bioscience, Inc. | 11.94 Million USD | 88.624% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | 96.503% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | 81.186% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -1679.02% |
| SQZ Biotechnologies Company | 107.18 Million USD | 98.733% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | 5.145% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -1777.086% |
| Mesoblast Limited | 667.9 Million USD | 99.797% |
| Marizyme, Inc. | 22.01 Million USD | 93.83% |
| Genus plc | 1.02 Billion USD | 99.868% |
| Pharming Group N.V. | 462.85 Million USD | 99.707% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | 58.999% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -172.194% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -116.643% |
| ContraFect Corporation | 20.67 Million USD | 93.431% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -247.969% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -255.425% |
| IMV Inc. | 31.33 Million USD | 95.665% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | 67.237% |
| MultiCell Technologies, Inc. | 126.22 USD | -1076078.894% |
| ONE Bio Corp. | 70.08 Million USD | 98.062% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -44.553% |
| RVL Pharmaceuticals plc | 128.51 Million USD | 98.943% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -214.642% |
| Q BioMed Inc. | 3.51 Million USD | 61.361% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | 96.139% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -419.89% |
| Biomind Labs Inc. | 73.81 Thousand USD | -1740.113% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | 99.696% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | 6.246% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | 95.474% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | 50.539% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -97.583% |
| Curative Biotechnology, Inc. | 2.6 Million USD | 47.82% |
| GB Sciences, Inc. | 103.44 Thousand USD | -1213.154% |
| Alpha Cognition Inc. | 2.45 Million USD | 44.606% |
| HST Global, Inc. | 1526.00 USD | -88913.958% |
| CSL Limited | 38.02 Billion USD | 99.996% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -37.49% |
| Halberd Corporation | 10.13 Thousand USD | -13307.887% |
| Enzolytics Inc. | 361.7 Million USD | 99.624% |
| Agentix Corp. | 261.39 Thousand USD | -419.661% |
| Resverlogix Corp. | 8.11 Million USD | 83.261% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | 27.666% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | 99.97% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | 97.152% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -112.357% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -5862.657% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | 84.821% |
| AVAX Technologies, Inc. | 7.37 Million USD | 81.587% |
| Zenith Capital Corp. | 7410.00 USD | -18231.35% |
| Genscript Biotech Corporation | 3.38 Billion USD | 99.96% |
| Ember Therapeutics, Inc. | 184.00 USD | -738135.326% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -322.103% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -419.717% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -46.38% |
| Kadimastem Ltd | 2.3 Million USD | 41.046% |
| Helix BioMedix, Inc. | 3.02 Million USD | 55.097% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 52.7 Million USD | 97.423% |
| BioStem Technologies, Inc. | 14.56 Million USD | 90.671% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -2279.152% |
| LadRx Corporation | 2.3 Million USD | 41.143% |
| Cell Source, Inc. | 195.17 Thousand USD | -595.981% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -284.131% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -284.131% |
| NovAccess Global Inc. | 62.24 Thousand USD | -2082.163% |
| Affymax, Inc. | 7.44 Million USD | 81.75% |
| Itoco Inc. | 1.4 Million USD | 2.98% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -1320.025% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -1181.465% |
| Mobile Lads Corp. | 52.00 USD | -2612117.308% |
| CytoDyn Inc. | 11.13 Million USD | 87.802% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -850.083% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -7497.053% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -252.388% |
| SYBLEU INC | 330.46 Thousand USD | -311.039% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -231.773% |
| International Stem Cell Corporation | 5.39 Million USD | 74.799% |
| Bioxytran, Inc. | 137.63 Thousand USD | -886.903% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | 90.945% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | 91.807% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -1619.434% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -57.094% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | 81.93% |
| Neutra Corp. | 2851.00 USD | -47544.791% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | 95.808% |
| PureTech Health plc | 693.97 Million USD | 99.804% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | 83.17% |
| IXICO plc | 15.84 Million USD | 91.427% |
| IntelGenx Technologies Corp. | 8.28 Million USD | 83.599% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 98.685% |
| CSL Limited | 38.02 Billion USD | 99.996% |
| Cellectis S.A. | 333.99 Million USD | 99.593% |